Trelegy Ellipta is the first once-daily single inhaler triple therapy approved in the US for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease ...
HealthDay News — A combination of fluticasone furoate and vilanterol reduces the rate of moderate or severe exacerbations among patients with chronic obstructive pulmonary disease (COPD), according to ...
Patients who received fluticasone furoate-vilanterol had a 9% lower risk for a first moderate or severe COPD exacerbation than those who received budesonide-formoterol (hazard ratio [HR], 0.91; 95% CI ...
Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA? Treatment with once-daily single-inhaler fluticasone ...
Trelegy Ellipta combines fluticasone furoate, an inhaled corticosteroid with umeclidinium, an anticholinergic and vilanterol, a long-acting β2-adrenergic agonist (LABA). The Food and Drug ...
Treatment with once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) triple therapy appears to be more efficacious in reducing ...
The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday approved sales of ...
For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol, according to ...
The US Food and Drug Administration (FDA) gave the marketing nod today to a novel once-daily inhaled therapy for the treatment of chronic obstructive pulmonary disease (COPD). In contrast to Advair ...
The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...
A greater proportion of patients achieved asthma clinical remission with the single inhaler triple therapy. Clinical remission is achievable in patients with moderate to severe asthma treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results